{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T23:48:47Z","timestamp":1768520927925,"version":"3.49.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T00:00:00Z","timestamp":1653955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Tamoxifen treatment may induce dysregulation of estrogen homeostasis, leading to the occurrence of related adverse reactions. However, the potential mechanisms are still unclear. The purpose of the present study was to uncover whether tamoxifen treatment would act on estrogen metabolism-related biological enzymes and the regulatory effect on estrogen homeostasis to clarify the key factors and potential mechanisms of adverse reactions caused by long-term use of tamoxifen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>Female SD rats were administrated with tamoxifen CMC-Na solution (p.o.) once daily for four weeks and then housed at room temperature. Serum, breast, liver, uterus, and ovarian tissues were obtained, and the effects of tamoxifen administration on estrogen homeostasis, the expression, and activity of estrogen metabolic enzyme were evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared with the control group, the estrogen homeostasis was disturbed and the expression and activity of UGT2B1 (homology with human UGT2B7) were significantly reduced in the rats administrated with tamoxifen. The inhibitory effect of tamoxifen on UGT2B7 was dominated by hydrophobic and \u03c0-\u03c0 stacking interactions, resulting in a concentration-dependent inhibition of UGT2B7 activity by tamoxifen and the imbalance of ligand-activated transcription factors, leading to abnormal regulation of UGT2B and disturbance of estrogen homeostasis, which in turn led to adverse reactions of tamoxifen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We established links between estrogen metabolism and tamoxifen administration and we proposed that the UGT2B inhibition was involved in the disturbance of estrogen homeostasis and the occurrence of tamoxifen-related adverse reactions.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40360-022-00574-6","type":"journal-article","created":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:34:56Z","timestamp":1654043696000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The inhibition of tamoxifen on UGT2B gene expression and enzyme activity in rat liver contribute to the estrogen homeostasis dysregulation"],"prefix":"10.1186","volume":"23","author":[{"given":"Zhixiang","family":"Hao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiahao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiqing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxing","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongjian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,31]]},"reference":[{"issue":"10071","key":"574_CR1","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S0140-6736(16)31392-7","volume":"389","author":"O Ginsburg","year":"2017","unstructured":"Ginsburg O, Bray F, Coleman MP, Vanderpuye V, Eniu A, Kotha SR, et al. The global burden of women's cancers: a grand challenge in global health. Lancet. 2017;389(10071):847\u201360.","journal-title":"Lancet."},{"issue":"1","key":"574_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.steroids.2006.10.009","volume":"72","author":"VC Jordan","year":"2007","unstructured":"Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids. 2007;72(1):7\u201325.","journal-title":"Steroids."},{"issue":"6","key":"574_CR3","first-page":"1980","volume":"9","author":"EV Jensen","year":"2003","unstructured":"Jensen EV, Jordan VC. The estrogen receptor: a model for molecular medicine. Clin Cancer Res. 2003;9(6):1980\u20139.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"574_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1124\/dmd.116.073437","volume":"45","author":"AK MacLeod","year":"2017","unstructured":"MacLeod AK, McLaughlin LA, Henderson CJ, Wolf CR. Application of mice humanized for CYP2D6 to the study of tamoxifen metabolism and drug-drug interaction with antidepressants. Drug Metab Dispos. 2017;45(1):17\u201322.","journal-title":"Drug Metab Dispos"},{"issue":"9869","key":"574_CR5","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","volume":"381","author":"C Davies","year":"2013","unstructured":"Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805\u201316.","journal-title":"Lancet."},{"issue":"19","key":"574_CR6","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, et al. 20-year risks of breast-Cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377(19):1836\u201346.","journal-title":"N Engl J Med"},{"issue":"5","key":"574_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/jnci\/dji057","volume":"97","author":"AJ Swerdlow","year":"2005","unstructured":"Swerdlow AJ, Jones ME. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst. 2005;97(5):375\u201384.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"574_CR8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10549-007-9612-x","volume":"108","author":"JE Mortimer","year":"2008","unstructured":"Mortimer JE, Flatt SW, Parker BA, Gold EB, Wasserman L, Natarajan L, et al. Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat. 2008;108(3):421\u20136.","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"574_CR9","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/BF00665698","volume":"27","author":"CK Cathcart","year":"1993","unstructured":"Cathcart CK, Jones SE, Pumroy CS, Peters GN, Knox SM, Cheek JH. Clinical recognition and management of depression in node negative breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 1993;27(3):277\u201381.","journal-title":"Breast Cancer Res Treat"},{"key":"574_CR10","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jsbmb.2019.03.002","volume":"189","author":"P Bhardwaj","year":"2019","unstructured":"Bhardwaj P, Au CC, Benito-Martin A, Ladumor H, Oshchepkova S, Moges R, et al. Estrogens and breast cancer: mechanisms involved in obesity-related development, growth and progression. J Steroid Biochem Mol Biol. 2019;189:161\u201370.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"574_CR11","doi-asserted-by":"publisher","first-page":"105507","DOI":"10.1016\/j.jsbmb.2019.105507","volume":"196","author":"S Parween","year":"2020","unstructured":"Parween S, DiNardo G, Baj F, Zhang C, Gilardi G, Pandey AV. Differential effects of variations in human P450 oxidoreductase on the aromatase activity of CYP19A1 polymorphisms R264C and R264H. J Steroid Biochem Mol Biol. 2020;196:105507.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"3","key":"574_CR12","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1158\/1055-9965.EPI-05-0801","volume":"15","author":"AE Cribb","year":"2006","unstructured":"Cribb AE, Knight MJ, Dryer D, Guernsey J, Hender K, Tesch M, et al. Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol Biomark Prev. 2006;15(3):551\u20138.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"574_CR13","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.bcp.2018.07.006","volume":"155","author":"X Zhou","year":"2018","unstructured":"Zhou X, Zhao Y, Wang J, Wang X, Chen C, Yin D, et al. Resveratrol represses estrogen-induced mammary carcinogenesis through NRF2-UGT1A8-estrogen metabolic axis activation. Biochem Pharmacol. 2018;155:252\u201363.","journal-title":"Biochem Pharmacol"},{"issue":"6","key":"574_CR14","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1002\/ijc.30728","volume":"141","author":"EL Cavalieri","year":"2017","unstructured":"Cavalieri EL, Rogan EG, Zahid M. Critical depurinating DNA adducts: estrogen adducts in the etiology and prevention of cancer and dopamine adducts in the etiology and prevention of Parkinson's disease. Int J Cancer. 2017;141(6):1078\u201390.","journal-title":"Int J Cancer"},{"issue":"2","key":"574_CR15","first-page":"135","volume":"27","author":"HC Guldberg","year":"1975","unstructured":"Guldberg HC, Marsden CA. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev. 1975;27(2):135\u2013206.","journal-title":"Pharmacol Rev"},{"key":"574_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1749-6632.2009.04114.x","volume":"1155","author":"P Lazarus","year":"2009","unstructured":"Lazarus P, Blevins-Primeau AS, Zheng Y, Sun D. Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen. Ann N Y Acad Sci. 2009;1155:99\u2013111.","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"574_CR17","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1016\/j.xphs.2017.04.073","volume":"106","author":"X Zhou","year":"2017","unstructured":"Zhou X, Zheng Z, Xu C, Wang J, Min M, Zhao Y, et al. Disturbance of mammary UDP-glucuronosyltransferase represses estrogen metabolism and exacerbates experimental breast Cancer. J Pharm Sci. 2017;106(8):2152\u201362.","journal-title":"J Pharm Sci"},{"issue":"1","key":"574_CR18","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/toxsci\/61.1.49","volume":"61","author":"C King","year":"2001","unstructured":"King C, Tang W, Ngui J, Tephly T, Braun M. Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac. Toxicol Sci. 2001;61(1):49\u201353.","journal-title":"Toxicol Sci"},{"issue":"11","key":"574_CR19","doi-asserted-by":"publisher","first-page":"918","DOI":"10.2174\/1389200220666191115103310","volume":"20","author":"Y Jarrar","year":"2019","unstructured":"Jarrar Y, Jarrar Q, Abu-Shalhoob M, Abed A, Sha'ban E. Relative expression of mouse Udp-glucuronosyl transferase 2b1 gene in the livers, kidneys, and hearts: the influence of nonsteroidal anti-inflammatory drug treatment. Curr Drug Metab. 2019;20(11):918\u201323.","journal-title":"Curr Drug Metab"},{"issue":"3","key":"574_CR20","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00204-017-2147-y","volume":"92","author":"J Joh\u00e4nning","year":"2018","unstructured":"Joh\u00e4nning J, Kr\u00f6ner P, Thomas M, Zanger UM, N\u00f6renberg A, Eichelbaum M, et al. The formation of estrogen-like tamoxifen metabolites and their influence on enzyme activity and gene expression of ADME genes. Arch Toxicol. 2018;92(3):1099\u2013112.","journal-title":"Arch Toxicol"},{"issue":"1","key":"574_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10549-011-1699-4","volume":"133","author":"WJ Lu","year":"2012","unstructured":"Lu WJ, Xu C, Pei Z, Mayhoub AS, Cushman M, Flockhart DA. The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents. Breast Cancer Res Treat. 2012;133(1):99\u2013109.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"574_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00280-008-0842-3","volume":"64","author":"S Harmsen","year":"2009","unstructured":"Harmsen S, Meijerman I, Beijnen JH, Schellens JH. Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor. Cancer Chemother Pharmacol. 2009;64(1):35\u201343.","journal-title":"Cancer Chemother Pharmacol"},{"key":"574_CR23","doi-asserted-by":"publisher","first-page":"113042","DOI":"10.1016\/j.jpba.2019.113042","volume":"180","author":"C Cohier","year":"2020","unstructured":"Cohier C, Salle S, Fontova A, M\u00e9garbane B, Roussel O. Determination of buprenorphine, naloxone and phase I and phase II metabolites in rat whole blood by LC-MS\/MS. J Pharm Biomed Anal. 2020;180:113042.","journal-title":"J Pharm Biomed Anal"},{"issue":"5","key":"574_CR24","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/ijgc-00009577-200209000-00015","volume":"12","author":"I Kloos","year":"2002","unstructured":"Kloos I, Delaloge S, Pautier P, Di Palma M, Goupil A, Duvillard P, et al. Tamoxifen-related uterine carcinosarcomas occur under\/after prolonged treatment: report of five cases and review of the literature. Int J Gynecol Cancer. 2002;12(5):496\u2013500.","journal-title":"Int J Gynecol Cancer"},{"issue":"9354","key":"574_CR25","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/S0140-6736(03)12342-2","volume":"361","author":"J Cuzick","year":"2003","unstructured":"Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361(9354):296\u2013300.","journal-title":"Lancet."},{"issue":"7","key":"574_CR26","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/jnci\/86.7.527","volume":"86","author":"B Fisher","year":"1994","unstructured":"Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and bowel project (NSABP) B-14. J Natl Cancer Inst. 1994;86(7):527\u201337.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"574_CR27","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1001\/jama.1980.03300320012005","volume":"243","author":"A Hendrick","year":"1980","unstructured":"Hendrick A, Subramanian VP. Tamoxifen and thromboembolism. JAMA. 1980;243(6):514\u20135.","journal-title":"JAMA."},{"issue":"9","key":"574_CR28","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1001\/archinte.1991.00400090120021","volume":"151","author":"RR Love","year":"1991","unstructured":"Love RR, Cameron L, Connell BL, Leventhal H. Symptoms associated with tamoxifen treatment in postmenopausal women. Arch Intern Med. 1991;151(9):1842\u20137.","journal-title":"Arch Intern Med"},{"key":"574_CR29","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/978-3-642-45769-2_38","volume":"152","author":"PA Ganz","year":"1998","unstructured":"Ganz PA, Rowland JH, Meyerowitz BE, Desmond KA. Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. Recent Results Cancer Res. 1998;152:396\u2013411.","journal-title":"Recent Results Cancer Res"},{"issue":"8","key":"574_CR30","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1056\/NEJM198902233200802","volume":"320","author":"B Fisher","year":"1989","unstructured":"Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320(8):479\u201384.","journal-title":"N Engl J Med"},{"key":"574_CR31","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/oxfordjournals.jncimonographs.a003450","volume":"30","author":"PA Ganz","year":"2001","unstructured":"Ganz PA. Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life. J Natl Cancer Inst Monogr. 2001;30:130\u20134.","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"9","key":"574_CR32","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1200\/JCO.1999.17.9.2659","volume":"17","author":"R Day","year":"1999","unstructured":"Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and bowel project P-1 study. J Clin Oncol. 1999;17(9):2659\u201369.","journal-title":"J Clin Oncol"},{"issue":"9574","key":"574_CR33","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/S0140-6736(07)60778-8","volume":"369","author":"J Cuzick","year":"2007","unstructured":"Cuzick J, Ambroisine L, Davidson N, Jakesz R, Kaufmann M, Regan M, et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet. 2007;369(9574):1711\u201323.","journal-title":"Lancet."},{"issue":"4","key":"574_CR34","doi-asserted-by":"publisher","first-page":"500","DOI":"10.2174\/0929867321666140916123022","volume":"22","author":"J Reinen","year":"2015","unstructured":"Reinen J, Vermeulen NP. Biotransformation of endocrine disrupting compounds by selected phase I and phase II enzymes--formation of estrogenic and chemically reactive metabolites by cytochromes P450 and sulfotransferases. Curr Med Chem. 2015;22(4):500\u201327.","journal-title":"Curr Med Chem"},{"key":"574_CR35","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/1471-2407-10-313","volume":"10","author":"J Gjerde","year":"2010","unstructured":"Gjerde J, Geisler J, Lundgren S, Ekse D, Varhaug JE, Mellgren G, et al. Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer. 2010;10:313.","journal-title":"BMC Cancer"},{"issue":"3\u20135","key":"574_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0960-0760(03)00365-0","volume":"86","author":"M Dowsett","year":"2003","unstructured":"Dowsett M, Haynes BP. Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. J Steroid Biochem Mol Biol. 2003;86(3\u20135):255\u201363.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"4","key":"574_CR37","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1158\/1078-0432.CCR-0433-03","volume":"10","author":"LM Berstein","year":"2004","unstructured":"Berstein LM, Wang JP, Zheng H, Yue W, Conaway M, Santen RJ. Long-term exposure to tamoxifen induces hypersensitivity to estradiol. Clin Cancer Res. 2004;10(4):1530\u20134.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"574_CR38","doi-asserted-by":"publisher","first-page":"850","DOI":"10.2174\/138920021610151210164501","volume":"16","author":"X He","year":"2015","unstructured":"He X, Feng S. Role of metabolic enzymes P450 (CYP) on activating Procarcinogen and their polymorphisms on the risk of cancers. Curr Drug Metab. 2015;16(10):850\u201363.","journal-title":"Curr Drug Metab"},{"issue":"1","key":"574_CR39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1210\/me.2009-0339","volume":"24","author":"CD DuSell","year":"2010","unstructured":"DuSell CD, Nelson ER, Wittmann BM, Fretz JA, Kazmin D, Thomas RS, et al. Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators. Mol Endocrinol. 2010;24(1):33\u201346.","journal-title":"Mol Endocrinol"},{"issue":"3\u20135","key":"574_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jsbmb.2011.05.001","volume":"126","author":"MY Williams-Brown","year":"2011","unstructured":"Williams-Brown MY, Salih SM, Xu X, Veenstra TD, Saeed M, Theiler SK, et al. The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk. J Steroid Biochem Mol Biol. 2011;126(3\u20135):78\u201386.","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"3","key":"574_CR41","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1007\/s00204-017-2139-y","volume":"92","author":"Z Lu","year":"2018","unstructured":"Lu Z, Lu Y, Wang X, Wang F, Zhang Y. Activation of intestinal GR-FXR and PPAR\u03b1-UGT signaling exacerbates ibuprofen-induced enteropathy in mice. Arch Toxicol. 2018;92(3):1249\u201365.","journal-title":"Arch Toxicol"},{"issue":"3","key":"574_CR42","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1124\/dmd.118.084947","volume":"47","author":"N Chau","year":"2019","unstructured":"Chau N, Kaya L, Lewis BC, Mackenzie PI, Miners JO. Drug and chemical Glucosidation by control Supersomes and membranes from Spodoptera frugiperda (sf) 9 cells: implications for the apparent Glucuronidation of Xenobiotics by UDP-glucuronosyltransferase 1A5. Drug Metab Dispos. 2019;47(3):271\u20138.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"574_CR43","doi-asserted-by":"publisher","first-page":"e0127524","DOI":"10.1371\/journal.pone.0127524","volume":"10","author":"L Lu","year":"2015","unstructured":"Lu L, Zhou J, Shi J, Peng XJ, Qi XX, Wang Y, et al. Drug-metabolizing activity, protein and gene expression of UDP-glucuronosyltransferases are significantly altered in hepatocellular carcinoma patients. PLoS One. 2015;10(5):e0127524.","journal-title":"PLoS One"},{"issue":"7","key":"574_CR44","doi-asserted-by":"publisher","first-page":"e0132269","DOI":"10.1371\/journal.pone.0132269","volume":"10","author":"A Romero-Lorca","year":"2015","unstructured":"Romero-Lorca A, Novillo A, Gaibar M, Bandr\u00e9s F, Fern\u00e1ndez-Santander A. Impacts of the Glucuronidase genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on tamoxifen metabolism in breast Cancer patients. PLoS One. 2015;10(7):e0132269.","journal-title":"PLoS One"},{"issue":"3","key":"574_CR45","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/clpt.2014.126","volume":"96","author":"C Guillemette","year":"2014","unstructured":"Guillemette C, L\u00e9vesque \u00c9, Rouleau M. Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications. Clin Pharmacol Ther. 2014;96(3):324\u201339.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"574_CR46","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/jps.21830","volume":"99","author":"R Fujiwara","year":"2010","unstructured":"Fujiwara R, Nakajima M, Oda S, Yamanaka H, Ikushiro S, Sakaki T, et al. Interactions between human UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A enzymes. J Pharm Sci. 2010;99(1):442\u201354.","journal-title":"J Pharm Sci"},{"issue":"1","key":"574_CR47","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1080\/13880209.2018.1525413","volume":"56","author":"G Dong","year":"2018","unstructured":"Dong G, Zhou Y, Song X. In vitro inhibitory effects of bergenin on human liver cytochrome P450 enzymes. Pharm Biol. 2018;56(1):620\u20135.","journal-title":"Pharm Biol"},{"issue":"5","key":"574_CR48","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s00280-004-0926-7","volume":"55","author":"YC Lim","year":"2005","unstructured":"Lim YC, Desta Z, Flockhart DA, Skaar TC. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol. 2005;55(5):471\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"574_CR49","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1124\/jpet.104.065607","volume":"310","author":"Z Desta","year":"2004","unstructured":"Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004;310(3):1062\u201375.","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"574_CR50","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1124\/dmd.114.059709","volume":"42","author":"EJ Squirewell","year":"2014","unstructured":"Squirewell EJ, Qin X, Duffel MW. Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014;42(11):1843\u201350.","journal-title":"Drug Metab Dispos"},{"key":"574_CR51","doi-asserted-by":"publisher","first-page":"107414","DOI":"10.1016\/j.pharmthera.2019.107414","volume":"204","author":"DG Hu","year":"2019","unstructured":"Hu DG, Hulin JU, Nair PC, Haines AZ, McKinnon RA, Mackenzie PI, et al. The UGTome: the expanding diversity of UDP glycosyltransferases and its impact on small molecule metabolism. Pharmacol Ther. 2019;204:107414.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"574_CR52","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3109\/03602530903219220","volume":"42","author":"M Verreault","year":"2010","unstructured":"Verreault M, Kaeding J, Caron P, Trottier J, Grosse L, Houssin E, et al. Regulation of endobiotics glucuronidation by ligand-activated transcription factors: physiological function and therapeutic potential. Drug Metab Rev. 2010;42(1):110\u201322.","journal-title":"Drug Metab Rev"},{"issue":"1","key":"574_CR53","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3109\/03602530903209544","volume":"42","author":"PI Mackenzie","year":"2010","unstructured":"Mackenzie PI, Hu DG, Gardner-Stephen DA. The regulation of UDP-glucuronosyltransferase genes by tissue-specific and ligand-activated transcription factors. Drug Metab Rev. 2010;42(1):99\u2013109.","journal-title":"Drug Metab Rev"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-022-00574-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-022-00574-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-022-00574-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T01:16:09Z","timestamp":1654046169000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-022-00574-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,31]]},"references-count":53,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["574"],"URL":"https:\/\/doi.org\/10.1186\/s40360-022-00574-6","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,31]]},"assertion":[{"value":"7 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complies with ARRIVE guidelines. All animal studies were conducted with the approval of and in accordance with rules and regulations of the Institutional Animal Care and Use Committee in Xuzhou Medical University, Xuzhou, China.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}